atients undergoing a cardiopulmonary crisis, who would previously not have survived under conventional emergency treatment, are now saved by mechanical cardiopulmonary support systems [intra-aortic balloon pump (IABP), percutaneous cardiopulmonary support (PCPS) and ventricular assist device (VAS)]. Fulminant myocarditis is one such disease in which patients can recover and return to normal life after being rescued from fatal cardiopulmonary crisis by mechanical cardiopulmonary support. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, this breakthrough in treatment has led to new problems, such as how to manage the mechanical cardiopulmonary support to improve survival, how to monitor the clinical course, and how to enhance the long-term prognosis of fulminant myocarditis.
Results

Clinical Characteristics and Prognosis of Fulminant Myocarditis Patients
Fifty-two patients were enrolled in the survey and their clinical characteristics are shown in Table 2 ; 30 (57.7%) patients survived and returned to normal life, 1 (1.9%) patient survived in a vegetative state and remained hospitalized, and 21 (40.4%) patients died. The average period from onset to admission was 4.67±3.46 days, and the period from admission to instituting PCPS was 0.90±1.54 days. On admission, half of the patients showed systolic blood pressure (SBP) of less than 90 mmHg, and approximately 60% of patients showed either tachycardia or bradycardia. Approximately 80% of patients had clear consciousness: 16 of the patients with clear consciousness, 3 with semiconsciousness and 1 who was in a coma on admission survived and returned to normal life. Not all patients were New York Heart Association (NYHA) functional classification IV on admission.
The initial and cardinal symptoms are summarized in Table 3 . Of the initial symptoms, increased fever, general fatigue and coughing were the most common, and of the cardinal symptoms, most were caused by congestive heart failure and low output syndrome. The results of the chest X-ray, electrocardiogram and echocardiogram of patients are shown in Table 4 . The chest X-rays were characterized by a slight dilatation of the heart and congestion of the lungs and approximately 80% of patients showed either sinus tachycardia or complete atrioventricular block on the ECG. Abnormal Q, poor r-progression and low voltage were common findings in addition to an ST-T abnormality on admission. The echocardiogram showed left ventricular dysfunction, slight hypertrophy and pericardial effusion without dilatation of the left atrium or ventricle. Table 5 shows the arterial blood gas analysis, full blood count and biochemical examination on admission. Most patients showed respiratory compensation of the metabolic acidosis, markedly increased leukocytes (WBC), increased myocardial releasing enzymes, renal dysfunction, hyponatraemia and increased C-reactive protein (CRP). One-third of the patients had thrombopenia. In particular, qualitative and quantitative analysis of troponin T (TNT) was more useful than creatine kinase (CK), because 19 (57.6%) of 33 patients who had TNT confirmed on admission did not show significant increases of CK or creatine kinase-MB (CK-MB). With (Table 6) , and a definitive diagnosis was made by endomyocardial biopsy. The total time required for setting up the PCPS was 186.9±134.4 h (7.8±5.6 days) and there was no significant difference in the time required between the groups.
Comparison of Survivors and Non-Survivors
The patients who survived (n=31), including the one non-rehabilitated patient, were compared with the patients who did not (n=21) ( Table 7) . However, there were items that could not be compared by date by a statistical method because of insufficient data: lactic acid (LA), uric acid (UA), ejection time (ET) and arterial blood carbon dioxide partial pressure (PaCO2). Non-survivors had a lower heart rate on admission and CK before undergoing PCPS, circulatory disturbances of the legs and multiple organ failure (MOF) associated with PCPS, maximum dosage of noradrenaline (NA) during PCPS, steroid pulse therapy or continuous hemofiltration (CHF) as concurrent treatments, the number of exchanges of PCPS, WBC, total bilirubin (TB), lactate dehydrogenase (LDH), CK-MB, TNT and blood urea nitrogen (BUN) during PCPS were significantly higher than those of the survivors. In the patients who survived, the number given phentolamine mesylate (PM) during PCPS, and the maximum percent left ventricular fractional shortening (%FS) and ejection fraction (EF) were significantly higher than for the non-survivors.
Comparison of the Patient Groups That Underwent PCPS for Low Output Syndrome (LOS) and LifeThreatening Arrhythmia (LTA)
The LOS patient group (n=28) included those who, despite cardiotonic or vasopressor drugs and IABP treatment, did not recover from the circulatory failure and then underwent PCPS. Those who did not recover from cardiac arrest or LTA despite every possible treatment and who then underwent PCPS were defined as the LTA group (n=24). There were no significant differences other than those shown in Table 8 between the 2 groups, but because of insufficient data, 2 items could not be compared by date by a statistical method: UA and ET. The severity of nausea and vomiting as the cardinal symptoms and the maximum left ventricle end-diastolic dimension (LVDd) during PCPS were higher in the LTA patients than in the LOS patients. The minimum EF during PCPS in the LOS patients was lower than that of the LTA patients. 
Comparison of the Survivors and Non-Survivors in the LOS Group
The survivors (n=20) and non-survivors (n=8) were compared and the significant differences are shown in Table 9 . However, the items that could not be compared by date by a statistical method because of insufficient data were: LA, UA, TNT, central venous pressure (CVP), cardiac index (CI) and pulmonary capillary wedge pressure (PCWP), stroke volume index (SVI), cardiothoracic rate (CTR), end-tidal carbon dioxide partial pressure (ETCO2), PaCO2, and echocardiographic data. The level of LDH and CK before undergoing PCPS, circulatory disturbances of the legs, MOF and disseminated intravascular coagulation (DIC) associated with PCPS, and maximum level of WBC, CK-MB and serum creatinine (Cr) during PCPS were higher in the non-survivors than in the patients who survived. In addition, the initial flow rate of PCPS and the minimum of pH during PCPS were lower in the patients who did not survive, and furthermore in the post-PCPS patients, the doses of dobutamine (DOB) (p=0.005) and Cr (p=0.013) were higher in the patients who did not survive than in those who did at the time of completion of PCPS.
Comparison of the Survivors and Non-Survivors in the LTA Group
The survivors (n=11) were compared with non-survivors (n=13) and the significant differences are shown in Table10. However, because of insufficient data, the following items could not be compared by date by a statistical method: LA, UA, TNT, mixed venous blood oxygen saturation (SVO2), CI, ETCO2, PaCO2, and ET. In the non-survivors, the period from admission to starting PCPS, the calcium level (Ca) on admission, circulatory disturbances of the legs and MOF associated with PCPS, maximum BUN and Cr during PCPS, the maximum dosage of NA during PCPS, and the number of patients requiring nafamostat during PCPS, globulin therapy or CHF as concurrent treatments were higher than in the survivors. The number of patients given PM during PCPS was higher in the survivors than nonsurvivors. Furthermore, comparison between survivors and non-survivors in the post-PCPS patients showed that CI (p=0.039) and PCWP (p=0.020) were lower in the nonsurvivors than survivors at the time of PCPS completion. However, CI and PCWP were unrelated to each other. The level of alanine aminotransferase (ALT [glutamic pyruvic transaminase: GPT]) (p=0.007), aspartate aminotransferase (AST [glutamic oxaloacetic transaminase: GOT]) (p=0.015) and BUN (p=0.020) in the non-survivors was higher than in the survivors at the time of PCPS completion.
Comparison of Patients Who Could and Those Who Could Not Be Weaned Off PCPS
Patients who could (n=42) and those who could not (n=10) be weaned off PCPS were compared and the significant differences are shown in Table 11 . However, because of insufficient data, the items that could not be compared by date by a statistical method were as follows: LA and TNT, CVP and SVO2, SVI and CVP, and CTR. In those 
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patients who could not be weaned off, the levels of CK-MB before undergoing PCPS, and circulatory disturbances of the legs and MOF associated with PCPS, and maximum AST, ALT, LDH, CK, CK-MB, Cr, EF and activated clotting time (ACT) during PCPS, and the maximum dosage of NA during PCPS, and the number of patients given isosorbide dinitrate (ISDN) during PCPS, and CHF as concurrent treatment, and minimum flow rate of PCPS were higher, and minimum pH, base excess (BE) and BPs during PCPS were lower than in those patients who could.
Comparison of the Survivors and Non-Survivors in the Post-PCPS Patients
Survivors (n=31) and non-survivors (n=11) in post-PCPS patients were compared and the significant differences are shown in Table 12 . However, because of insufficient data, the items that could not be compared by date by a statistical method were: LA, UA, SVO2, SVI, TNT, PaCO2 and ET. In the non-survivors, low voltage on admission, and circulatory disturbances of the legs and MOF associated with PCPS, and maximum levels of BUN and Cr during PCPS, and AST, ALT, BUN and Cr were higher and the initial flow rate of PCPS, PCWP and CK were lower than those of survivors at the time of PCPS completion.
Long-Term Prognosis
The 30 survivors who returned to normal life (n=30) comprised the study group (Table13). In the average followup period of 962 days, the readmission rate was 10%, exacerbation rate 3.3%, and mortality was 10% (Table 14) .
Of the readmitted patients (n=3), 2 had congestive heart failure and 1 had recurrence of the myocarditis. All readmitted patients had abnormally increased WBC and CRP during follow-up; one showed poor r-progression on the ECG, a decrease of EF on the echocardiogram and exacerbation of 123 I-metaiodobenzyl-guanidine (MIBG) and 123 I--methyl-iodophenyl pentadecanoic acid (BMIPP) on single photon emission computed tomography (SPECT), and 2 showed dilatation of LVDd on the echocardiogram. Of the non-survivors (n=3), 2 died of congestive heart failure, and 1 died of exacerbation of rheumatoid arthritis.
Concerning medication, 12 patients had none at dis- sion, half of the patients had a SBP less than 90 mmHg, and approximately 60% of the patients had either tachycardia or bradycardia. The ECG on admission revealed that approximately 80% of patients had either sinus tachycardia or complete atrioventricular block, and an ST-T abnormality, abnormal Q wave, low voltages or poor r-progression were often present as well. On the chest X-ray on admission, about 70% of the patients showed congestion of the lungs and slight dilatation of the heart. Echocardiography showed left ventricular dysfunction, slight hypertrophy and pericardial effusion without dilatation of the left atrium or ventricle. Arterial blood gas analysis, full blood count and biochemical examination revealed that respiratory compensation for the metabolic acidosis, markedly increased WBC, increased myocardial releasing enzyme, renal dysfunction, hyponatraemia and increased CRP were common findings.
Even if the vital signs are stable on admission, a few patients can suddenly LOS or LTA, so it is necessary to closely observe all such patients with periodic Swan-Ganz catheterization, ECG, echocardiography, full blood count and blood biochemistry, and to prepare for life-support systems. It is important to rapidly confirm the diagnosis with coronary angiography and endomyocardial biopsies, without jeopardizing the patient's clinical condition, because a positive indication for mechanical cardiopulmonary support is required to avoid overuse and a possible negative result.
Comparison Between Each Patient Group and the Prognosis Relation Factor
Differences Between Survivors and Non-Survivors The differences can be summarized as follows. (1) The occurrence of complications associated with PCPS, especially circulatory disturbances of the legs and MOF, affect the prognosis, and symptomatic treatment for MOF was frequently performed in the non-survivors.
(2) The myocardial damage in the non-survivors was more severe than in the survivors.
(3) The improvement of left ventricular contractility during PCPS in the survivors was better than in the nonsurvivors.
(4) In the non-survivors, steroid pulse therapy was frequently administered as a concurrent treatment, but whether it made the myocarditis worse or not was uncertain.
Differences Between the Survivors and Non-Survivors in Each Group Classified by Indication for PCPS
The differences between the survivors and non-survivors in the LOS group are summarized as follows.
(1) In the non-survivors, LDH and CK before undergoing PCPS were higher than in the survivors. High levels of LDH and CK in LOS patients before undergoing PCPS were reliable indicators of a poor prognosis.
(2) In the non-survivors, it was necessary to frequently adjust the support flow rate during PCPS to that which would facilitate recovery from circulatory failure.
(3) The occurrence of complications associated with PCPS, especially circulatory disturbances of the legs and MOF, affected the prognosis.
(4) The myocardial damage in the non-survivors was more severe than in the survivors.
The differences between the survivors and non-survivors in the LTA group are as follows.
(1) The occurrence of complications associated with PCPS, especially circulatory disturbances of the legs and MOF, affected the prognosis, and symptomatic treatment and CHF or nafamostat for MOF were more frequently required by non-survivors.
(2) In the non-survivors, globulin therapy was frequently required as a concurrent treatment, but whether it made the myocarditis worse or not was uncertain.
Differences Between Patients Who Could and Could Not Be Weaned Off PCPS The differences are summarized as follows.
(1) The occurrence of complications associated with PCPS, especially circulatory disturbances of the legs and MOF, affected the prognosis, and symptomatic treatment for MOF was frequently performed in the patients who could not be weaned off PCPS.
(2) Myocardial damage in the patients who could not be weaned off PCPS was more severe than in the patients who could complete PCPS.
(3) Improvement of EF during PCPS in the patients who could complete PCPS was better than in the patients who could not.
Differences Between the Survivors and Non-Survivors in the Post-PCPS Patient Group
The differences are summarized as follows.
(1) In the non-survivors, it was necessary to frequently adjust the support flow rate that facilitated recovery from circulatory failure.
(2) The occurrence of complications associated with PCPS, especially circulatory disturbances of the legs and MOF, affected the prognosis.
(3) Renal dysfunction during PCPS in the non-survivors was more serious than in the survivors.
Noteworthy factors concerning the prognosis are as follows.
(1) The severity and level of improvement of cardiac and renal dysfunction.
(2) Adjustment of the support flow rate. (3) Prevention of circulatory disturbances of the legs and MOF.
Therapeutic Guidelines for the Use of PCPS for Fulminant Myocarditis
Based on the results of the survey, management guidelines for using PCPS to improve the survival rate of fulminant myocarditis patients were discussed and proposed (Fig 1) . In addition, these guidelines were based on recent data of 40 fulminant myocarditis patients treated with PCPS from Japan and overseas. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The fundamental concepts were appropriate adjustment of the support flow rate that would facilitate recovery from circulatory failure while constantly checking certain indicators of circulatory failure and cardiac function, and prevention of complications associated with PCPS.
The indications for PCPS for fulminant myocarditis were ultimately the development of LTA or LOS, especially those patients who did not recover from cardiac arrest or LTA despite every possible treatment. However, the decision to use PCPS should be made with consideration of the quality of resuscitation in cases of cardiopulmonary arrest that occurred pre-admission. The indication for PCPS in LOS has not been clearly determined yet, so it is important to base the decision on the indicators of circu- latory failure; that is, if despite cardiotonic or vasopressor drugs and IABP treatment, the patient does not recover from circulatory failure, PCPS should be instituted. Overuse or using PCPS without following this procedure must be avoided, because complications associated with PCPS often become the cause of death.
The initial flow rate is usually 3-3.5 L/min, and then the support flow rate that induces recovery from circulatory failure is determined by referring to the indicators of circulatory failure. After recovery, the lowest flow rate without circulatory failure is usually recommended for possible long-term use. In LOS patients, the initial flow rate in the non-survivors was lower than in the survivors and furthermore, in the post-PCPS patients, renal dysfunction during PCPS in the non-survivors was more serious than in the survivors, and the initial flow rate in the non-survivors was lower than in the survivors. It is paramount to prevent renal dysfunction and MOF by setting the correct initial flow rate.
The present investigation made clear that patients with circulatory disturbances of the legs or MOF associated with PCPS had a poor prognosis. Delay in instituting PCPS or managing the non-recovery from shock often led to MOF. It is necessary to shorten the period of shock, to decide the indication for PCPS appropriately and to correctly adjust the support flow rate. The circulatory disturbances of the legs tended to be caused by cannulation during cardiopulmonary resuscitation, so in patients who are candidates for PCPS, sheaths should be previously inserted in the femoral artery and vein and immediately after PCPS is begun, a bypass should be established between the artery of the legs and the arterial inflow catheter, because once ischemic signs appear, establishing such a bypass is useless. When the indicators of cardiac function have improved, reduction of the support flow rate can be attempted. When the patient's condition can be stabilized to the standards without exacerbation of circulatory failure and cardiac function at the flow rate 1.0 L/min, the patient should be reevaluated for cessation of PCPS. It is also important to try to complete PCPS as soon as possible in order to prevent the development of complications associated with PCPS.
We have also tried to verify whether the proposed guidelines are helpful or not. The enrolled patients with fulminant myocarditis were divided into 3 groups: those subjects who underwent PCPS in accordance with the proposed guidelines were defined as the excellently treated group, and those who did not were defined as the poorly treated group; those who were hard to differentiate because of insufficient data were put into the unknown group. The usefulness of the guidelines has been documented with significant differences in each group (Table 15 ). In the comparison between the survivors and non-survivors, it was calculated that 25 (86.2%) patients survived in the excellent group (n=29) and 17 (89.5%) patients died in the poor group (n=19). The problems identified in the poor group were: delay in instituting PCPS (6/17 patients: 35.3%), poor adjustment of the flow rate (16/17 patients: 94.1%), non-standard completion of PCPS (4/17 patients: 23.5%), and circulatory disturbances of the legs and MOF associated with PCPS (10/17 patients: 58.8%). Despite a good prediction in the excellent group, 4 patients died because of cardiac dysfunction (half of the patients did not recover full contractility), circulatory disturbances of the legs and MOF. Accordingly, it is important to develop a curative and radical treatment for myocardial inflammation in order to achieve less mortality than is the current status
Long-Term Prognosis of Patients Treated With PCPS
The readmission rate was 10%, exacerbation rate 3.3%, and mortality 10% in the average follow-up period of 962 days (Table 14) . The follow-up leukocyte count, CRP, ECG, echocardiogram and 123 I-MIBG were good methods for detecting cardiac events. Observation of the clinical course of the 17 patients without medication was carried out, as well as of the 10 patients who were taking medication for chronic heart failure. However, it is not yet clear whether patients need to continue or discontinue their medication.
McCarthy et al reported the long-term outcome of fulminant myocarditis patients as compared with acute nonfulminant myocarditis patients, and 93% of the patients survived without having received a heart transplant. The use of a circulatory-assist device appeared to be highly beneficial and it seemed that cardiac transplantation could be avoided in most cases. 1 Certainly, fulminant myocarditis can be a clinical entity with an excellent long-term prognosis: in the present survey, 90% of the survivors who were treated with PCPS were reported to be alive, although the survival rate remained at 57.7%. Accurate management of mechanical cardiopulmonary support systems and the development of a cure for myocarditis are the promising influences on the outcome of fulminant myocarditis.
Study Limitations
The patients were divided into different classes and compared by their data. Obvious causes with significant difference by statistical method could hardly be detected, because several causes were compounded, such as association with myocarditis itself, PCPS, side effects of therapy, complications and MOF. The causes were not always conclusive because of insufficient data. However, as far as making a decision according to clinical information and circumstantial evidence, we can conclude that the causes are noteworthy factors affecting the prognosis.
The lack of data for some aspects prevented us from always comparing the data by a statistical method and further analysis is necessary with detailed data.
The proposed therapeutic guidelines also referred to other published data, but we evaluated the guidelines using the present national survey only. We propse carrying out further investigation to verify or improve the guidelines.
